HCWB HCW Biologics Inc.
Legal ·
BE&K Building Group sued HCW Biologics, Cogent Bank and subcontractors in Broward County over unpaid renovation invoices. Fisk Electric's suit was consolidated, and Cogent Bank has demanded the liens be cleared.
The company agreed to sell 618,682 units at $2.585 per unit, including shares to its founder, chairman and an officer, and the common warrants need stockholder approval.
A Nasdaq Hearings Panel found HCW Biologics (Nasdaq: HCWB) back in compliance with the minimum bid price rule. The company faces a mandatory panel monitor and will effect a one-for-six reverse stock split on June 30, 2026.
The company priced 2,846,975 units at $1.405 each to a group of healthcare investors, and the warrants are exercisable at $1.28 per share.
The company reported $6.5 million in revenue and net income of $3.5 million for the quarter ended March 31, 2026, and it still states substantial doubt about going concern.
A Nasdaq Hearings Panel granted HCW Biologics (Nasdaq: HCWB) continued listing on October 13, 2025. The company must show compliance with the Equity Rule by December 31, 2025 and with all other rules by February 16, 2026.
Nasdaq says HCW Biologics was out of compliance with its equity rule on June 30, 2025. The shares would be suspended on August 28 unless the company asks for a hearing by August 26.
HCW Biologics says it needs more time to finish its June quarter 10-Q and expects to file within the five-day grace period. The notice gives no revenue, loss or cash figures.
Each unit carries two warrants exercisable at $7.45, and Maxim Group was sole placement agent. The prospectus carries going-concern doubt and a Nasdaq compliance warning.
HCW Biologics Inc. is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for diseases promoted by chronic inflammation, including autoimmune disorders, other proinflammatory diseases, cancer and senescence-associated dysplasia. It builds these molecules on two platforms: TOBI, which uses a Tissue Factor scaffold, and TRBC, which uses a T-cell Receptor beta chain constant region scaffold. Its lead clinical candidate, HCW9302, is an injectable IL-2 fusion protein that activates regulatory T cells. The first patient was dosed on November 17, 2025, in a first-in-human trial in alopecia areata. Beijing Trimmune Biotech Co., Ltd. has an option to license HCW9302 rights for China. HCW11-006 is being developed with Trimmune, which holds exclusive worldwide rights for in vivo applications of that compound. The company has begun commercializing two commercial-ready reagents, HCW9206 and HCW9201, for producing CAR-therapies and natural killer cell-based therapies. A Science Advances publication on March 13, 2026, reported company data on HCW9206 in CAR-T cell manufacturing.
| Product or program | What it is | Stage |
|---|---|---|
| HCW9302 | Injectable IL-2 fusion protein that activates regulatory T cells, in alopecia areata | clinical-stage |
| HCW9206 | Fusion protein reagent for producing CAR-therapies | commercial-ready |
| HCW9201 | Fusion protein reagent for producing natural killer cell-based therapies | commercial-ready |
| HCW11-018b | Tetra-valent T-cell engager designed to treat solid tumors | preclinical |
| HCW11-006 | Multi-functional immune cell stimulator developed with Trimmune | preclinical |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $5.4 million | $6.4 million |
| Net income (loss) | -$8.0 million | -$30.0 million |
| Cash from operations | -$13.4 million | -$14.2 million |
| Cash and equivalents | $2.0 million | $4.7 million |
| Short-term investments | $0 | $0 |
Our latest story on this, dated Jun 30, 2026: "HCW Biologics regains Nasdaq bid price compliance, faces monitor until June 17, 2027". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 14, 2026: "HCW Biologics reports first-quarter 2026 net income on Trimmune license". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 29, 2026: "HCW Biologics prices $1.6 million private placement with insiders and a stockholder". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 14, 2026: "HCW Biologics faces December jury trial in Florida mechanics lien foreclosure case". The story links the filing or release it is based on. Read the story.
HCW Biologics Inc. trades under the ticker HCWB on NASDAQ.
HCW Biologics Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for HCW Biologics Inc. is 1828673. Its filings are on SEC EDGAR.
1,836,324 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-14.
Our directory records HCW Biologics Inc. under United States.
Our directory classifies HCW Biologics Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for HCW Biologics Inc. is US40423R3030.
aibio.space lists HCW Biologics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
HCW Biologics Inc. is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for diseases promoted by chronic inflammation, including autoimmune disorders, other proinflammatory diseases, cancer and senescence-associated dysplasia. It builds these molecules on two platforms: TOBI, which uses a Tissue Factor scaffold, and TRBC, which uses a T-cell Receptor beta chain constant region scaffold.
HCW9302: Injectable IL-2 fusion protein that activates regulatory T cells, in alopecia areata Stage: clinical-stage.
Said earlier financial statements should no longer be relied on. SEC Form 8-K (Items 4.02). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,7.01,8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,8.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio